Press Releases CRISPR Therapeutics AG

Stocks

CRSP

CH0334081137

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 16/07/2026 am IST			After hours 05:26:50 am
51.37 ^USD	+1.80%		47.68	-7.18%

30/06	CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark	CI
30/06	CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell 2500 Growth Benchmark	CI

Press Releases

28/05	CRISPR Therapeutics to Participate in Upcoming Investor Conferences	AQ
06/05	CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference	AQ
05/05	CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results	AQ
07/04	CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference	AQ
11/03	CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering	AQ
10/03	CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering	AQ
25/02	Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026	AQ
13/02	CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results	AQ
12/01	CRISPR Therapeutics : JP Morgan 2026 (cb24d4)	PU
12/01	CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones	AQ
05/01	CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
22/12	CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies	AQ
09/12	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions	AQ
10/11	CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results	AQ
08/11	CRISPR Therapeutics : AHA 2025 (CTX310) (74f20d)	PU
08/11	CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering	AQ
13/25/13	CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency Utilizing Novel SyNTase Editing Platform	AQ
10/25/10	CRISPR Therapeutics : ESGCT 2025 (CTX460) (4b76e9)	PU
10/25/10	CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform	AQ
03/25/03	Australias Largest University Establishes Monash Boston Hub to Accelerate Global Biotech Partnerships and Licensing	AQ
01/25/01	CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress	AQ
22/25/22	CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe	AQ
10/25/10	CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025	AQ
02/25/02	CRISPR Therapeutics to Participate in Upcoming Investor Conferences	AQ
05/25/05	CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results	AQ